Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.52 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229126 | 0.92 | OTC (0.54) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL16242830 | 0.92 | NOD1 (0.56) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL13611057 | 0.92 | NOD1 (0.56) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL13611101 | 0.92 | OTC (0.54) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL16242697 | 0.90 | NOD1 (0.58) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL16242645 | 0.90 | NOD1 (0.58) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL16242519 | 0.90 | NOD1 (0.58) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL19034804 | 0.90 | NOD1 (0.58) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL19034985 | 0.90 | NOD1 (0.58) | OTCGSRGRM8GRM6GRIN2D | |
| SCHEMBL16242820 | 0.90 | NOD1 (0.58) | OTCGSRGRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169403-B9 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2023288313-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20210363185-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2021-11-25 | — | — | US | disclosed |
| WO-2017011820-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | disclosed |
| WO-2016011208-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20140170066-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | MERCK & CO., INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170066-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | MERCK & CO., INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8444764-B2 | Setting retarder for hydraulically setting compositions | SIKA TECHNOLOGY AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20110165075-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | MERCK SHARP & DOHME CORP. | 2011-07-07 | — | — | US | disclosed |
| US-20110165075-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | MERCK SHARP & DOHME CORP. | 2011-07-07 | — | — | US | disclosed |
| WO-2009114776-A2 | INTEGRIN TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | OTC 4590/4885GSR 3905/4885GRM8 2434/4885 |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | OTC 3996/4885GSR 3415/4885GRM8 2866/4885 |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | OTC 828/4885GSR 491/4885GRM8 619/4885 |
| US-20110165075-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | ITGB3, ITGAV, ITGB1 | OTC 4877/4885GSR 4653/4885GRM8 1607/4885 |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | OTC 4590/4885GSR 3905/4885GRM8 2434/4885 |
| US-20210363185-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | OTC 2627/4885GSR 2572/4885GRM8 2935/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | OTC 4590/4885GSR 3905/4885GRM8 2434/4885 |
| US-20140170066-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | ITGB3, ITGAV, ITGB1 | OTC 4877/4885GSR 4653/4885GRM8 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.